Prothena achieves $50M clinical milestone payment from Novo Nordisk

The company states: “Prothena (PRTA) announced that the Company earned a $50 million milestone payment from Novo Nordisk (NVO) related to the achievement of a prespecified enrollment target in the ongoing Phase 3 CLEOPATTRA clinical trial evaluating coramitug, a potential first-in-class amyloid depleter antibody, for the treatment of ATTR amyloidosis with cardiomyopathy. Novo Nordisk is evaluating coramitug in the ongoing Phase 3 CLEOPATTRA clinical trial in approximately 1280 participants with ATTR-CM with primary completion expected in 2029.”